PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
Aim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. Th...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-09-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839576721791123456 |
|---|---|
| author | O. L. Barbarash N. V. Fedorova D. Yu. Sedykh O. V. Gruzdeva O. N. Khryachkova V. V. Kashtalap A. A. Filimonova |
| author_facet | O. L. Barbarash N. V. Fedorova D. Yu. Sedykh O. V. Gruzdeva O. N. Khryachkova V. V. Kashtalap A. A. Filimonova |
| author_sort | O. L. Barbarash |
| collection | DOAJ |
| description | Aim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. The main inclusion criterion was nonachievement of target low-density lipoprotein cholesterol (LDL-C) values (<1,4 mmol/L) with high-intensity statin therapy prior to ACS. During the first 30 days after ACS, all patients received therapy with atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg/day in combination with alirocumab 150 mg/ml (Praluent) administered by subcutaneous injection. Lipid and biochemical profiles were monitored. The first injection of the PCSK9 inhibitor was performed on days 3-5 of hospitalization, the second — after 2 weeks.Results. On admission, the median LDL-C was 4,3 [3,5;5,3] mmol/L. A day after administration, there was a decrease in LDL-C by 41,9% (median 2,5 [1,8;3,2] mmol/L; p=0,001) without a negative effect on high-density lipoproteins (HDL-C) (median 1,2 [0,8;1,4] mmol/L; p=0,270). Before the next injection, LDL-C decreased by another 8% (median 2,3 [1,1;4,1] mmol/L). A day after the second injection, a decrease in LDL-C from the baseline values was 69,8% (median 1,3 [0,7;1,5] mmol/L; p=0,010). Strengthening lipid-lowering therapy with a PCSK9 inhibitor within 30 days after ACS did not lead to clinical and biochemical deterioration.Conclusion. The use of subcutaneous 150-mg injections of alirocumab 2 times a week 30 days after ACS in patients who did not reach target LDL-C values with statin therapy, leads to a 69% decrease in LDL-C from baseline values and is safe. |
| format | Article |
| id | doaj-art-a70e4c6dd04442cbb050b9ecd62ded4f |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2020-09-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-a70e4c6dd04442cbb050b9ecd62ded4f2025-08-04T13:00:22Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-09-0125810.15829/1560-4071-2020-40103006PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disordersO. L. Barbarash0N. V. Fedorova1D. Yu. Sedykh2O. V. Gruzdeva3O. N. Khryachkova4V. V. Kashtalap5A. A. Filimonova6Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical UniversityResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical UniversityResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical UniversityI. P. Pavlov Ryazan State Medical UniversityAim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. The main inclusion criterion was nonachievement of target low-density lipoprotein cholesterol (LDL-C) values (<1,4 mmol/L) with high-intensity statin therapy prior to ACS. During the first 30 days after ACS, all patients received therapy with atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg/day in combination with alirocumab 150 mg/ml (Praluent) administered by subcutaneous injection. Lipid and biochemical profiles were monitored. The first injection of the PCSK9 inhibitor was performed on days 3-5 of hospitalization, the second — after 2 weeks.Results. On admission, the median LDL-C was 4,3 [3,5;5,3] mmol/L. A day after administration, there was a decrease in LDL-C by 41,9% (median 2,5 [1,8;3,2] mmol/L; p=0,001) without a negative effect on high-density lipoproteins (HDL-C) (median 1,2 [0,8;1,4] mmol/L; p=0,270). Before the next injection, LDL-C decreased by another 8% (median 2,3 [1,1;4,1] mmol/L). A day after the second injection, a decrease in LDL-C from the baseline values was 69,8% (median 1,3 [0,7;1,5] mmol/L; p=0,010). Strengthening lipid-lowering therapy with a PCSK9 inhibitor within 30 days after ACS did not lead to clinical and biochemical deterioration.Conclusion. The use of subcutaneous 150-mg injections of alirocumab 2 times a week 30 days after ACS in patients who did not reach target LDL-C values with statin therapy, leads to a 69% decrease in LDL-C from baseline values and is safe.https://russjcardiol.elpub.ru/jour/article/view/4010dyslipidemiaacute coronary syndromepcsk9 inhibitorsalirocumab |
| spellingShingle | O. L. Barbarash N. V. Fedorova D. Yu. Sedykh O. V. Gruzdeva O. N. Khryachkova V. V. Kashtalap A. A. Filimonova PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders Российский кардиологический журнал dyslipidemia acute coronary syndrome pcsk9 inhibitors alirocumab |
| title | PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| title_full | PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| title_fullStr | PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| title_full_unstemmed | PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| title_short | PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| title_sort | pcsk9 inhibitors for in hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders |
| topic | dyslipidemia acute coronary syndrome pcsk9 inhibitors alirocumab |
| url | https://russjcardiol.elpub.ru/jour/article/view/4010 |
| work_keys_str_mv | AT olbarbarash pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT nvfedorova pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT dyusedykh pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT ovgruzdeva pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT onkhryachkova pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT vvkashtalap pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders AT aafilimonova pcsk9inhibitorsforinhospitaltreatmentofpatientswithacutecoronarysyndromeandseverelipidmetabolismdisorders |